Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX001899 Combinations in Advanced KRAS G12C NSCLC
NCT06946927Phase 1Recruiting
- Sponsor
- Jemincare
- Start
- Jun 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sosimerasib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Jemincare. Primary endpoints: Recommended Phase II Dose at 1 year and Adverse Events at 2.5 years. Started Jun 2025; status: recruiting.
02
Drugs
sosimerasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06946927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06946927.